OBJECTIVES: Aortic insufficiency (AI) after continuous-flow left ventricular assist device (CF-LVAD) implantation has become a highly relevant subject. However, management of pre-existing mild AI is unknown. We examined the fate of pre-existing mild AI during CF-LVAD support. RESULTS: Group A patients were more likely to have destination therapy intent at device insertion than Group B. Otherwise both groups displayed similar clinical/echocardiographic findings at baseline. There was no difference with respect to the occurrence of postoperative adverse events between groups. Kaplan-Meier analyses revealed the estimated 2-year on-device survival to be 63.3 ± 10.7 and 84.0 ± 10.6% (P = 0.41) and freedom from AI > _moderate at 2 years to be 81.8 ± 9.7 and 45.0 ± 21.1% (P = 0.031) in Groups A and B, respectively. Furthermore, 83.3% (5 of 6) of Group B patients with large (>1.94 cm/m 2 ; 75th percentile) body surface area-indexed aortic diameter developed > _moderate AI, while none of the Group B individuals with smaller aortic root (0 of 9) did. In contrast, Group A patients with large indexed aortic root (n = 7) have all been free of AI at 2 years.
INTRODUCTION
With the evolution of technology and patient management, continuous-flow left ventricular assist device (CF-LVAD) use has grown rapidly [1] . With an increasing number of patients with longer term usage of CF-LVAD, the management of pre-existing valvular lesions has become compelling, particularly progressive aortic insufficiency (AI), either de novo or as a progression from pre-existing AI [2, 3] . Patients with pre-existing AI have undergone aortic valve (AV) surgery concomitantly or post-implant, including AV closure, AV repair with varied techniques [4, 5] , AV replacement with a bioprosthesis [6] and more recently percutaneous device closure [7] . Central aortic valve closure (CAVC), first described by Park et al. [8] , has been a commonly practiced strategy to eliminate central regurgitation while allowing valve opening through lateral aspect of the leaflets. We have reported the largest series of this technique by demonstrating its efficacy and durability in this population [9] . However, there is little data regarding the applicability of this strategy and the degree of AI needed to be present to warrant concurrent repair. The current consensus recommends more than mild AI should undergo repair or biological prosthetic valve replacement, especially if lengthy device support is likely [10] . Accordingly, only patients with baseline AI >mild appeared to have received CAVC in previous series [11, 12] .
It is of critical importance to note that the majority of past studies describing this technique were lacking the comparison of repair and non-repair groups stratified by baseline AI degree. In addition, Jorde et al. demonstrated that at least moderate AI is expected to develop in 37.6% patients after 3 years of device support even in patients without pre-existing AI [3] . Therefore, it is imperative to investigate whether patients with pre-existing mild degree AI, which is clinically considered 'borderline disease', would benefit from concurrent repair at device insertion.
METHODS
The Columbia University Institutional Review Board approved all aspects of the present study. Abstracted data, retrieved from a prospectively maintained institutional database that is updated weekly, included the following: patient demographics, clinical and treatment variables, cardiopulmonary bypass and aortic cross-clamp times, blood product usage, dosage of vasoactive drugs at device implantation, perioperative/follow-up echocardiographic variables, adverse events and survival. All patients were followed at our institution, and records of these visits were examined. Follow-up was complete as of 1 June 2016.
Patients and study design

Echocardiographic assessment and follow-up of aortic insufficiency
Details of our protocol for echocardiographic evaluation have been reported elsewhere [13] . In brief, serial transthoracic echocardiography (TTE) and intraoperative transoesophageal echocardiography evaluations, reviewed by the same group of echocardiographers, were performed in all patients. The presence of AI was determined at baseline prior to device implant, and until time of last follow-up or censoring event as clinically indicated, typically at 30 days, 3 months, 6 months and annually afterwards. AI was evaluated using echocardiographic parameters of vena contracta width and visual estimation based on AI jet width in the parasternal short-and long-axis views. AI was graded as none, trace, mild, mild to moderate, moderate, moderate to severe and severe. The aortic root diameter was measured at the maximal diameter of the sinuses of Valsalva in the parasternal long-axis view. All measurements were taken in accordance with the American Society of Echocardiography guidelines [14] .
Indications and operative technique of central aortic valve closure
We began performing CAVC in 2009. All patients with preexisting greater than mild AI received a concurrent CAVC since then. For patients with mild AI, the decision to perform a repair was based on the following factors: anticipated prolonged device support such as destination therapy (DT), bridge-to-transplant patients with large body size (body mass index >35) and bridgeto-transplant patients with blood type O. Cardiopulmonary bypass was established with the standard aorto-atrial cannulation unless bicaval cannulation was necessary for other procedures. A transverse aortotomy was made to approach the AV after aortic cross-clamping and cardioplegia administration. The repair was performed by approximating the centre of the leaflets with a 4-0 pledgeted polypropylene suture. After completion of the repair and aortotomy closure, the aortic cross-clamp was removed. The rest of the procedure was conducted in the usual fashion with a beating heart.
Statistical analysis
Continuous variables are expressed as mean ± 1 SD. Categorical variables are presented as proportions and absolute numbers. Differences in categorical variables were detected using v 2 or Fischer's exact test. The Mann-Whitney U or Student's t-test were used to detect differences in continuous variables. Survival and freedom from greater than moderate were estimated using the Kaplan-Meier method and compared with log-rank test. Patients were censored for transplant, device explant or death. Device support duration was calculated from the date of first device implant. A P-value <0.05 was considered to be statistically significant. All P-values were results of 2-tailed tests. The statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA).
RESULTS
Patient baseline characteristics
Patient demographic and clinical variables are shown in Table 1 . Group A patients were more likely to have planned DT at the time of device insertion than Group B. Concurrent CAVC was more often performed in relatively recent patients. One Group B patient with DT intent did not receive a repair due to the presence of porcelain aorta. Two DT patients in Group B received a device before 2009 and therefore did not undergo a concurrent CAVC. No patients in Group B had body mass index >35, whereas 5 (12.2%) in Group A had. Otherwise both groups displayed similar clinical characteristics in terms of age, gender, heart failure aetiology, medical comorbidities, vasoinotropic agents, intra-aortic balloon pump use, mechanical ventilation and Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) patient profile at the time of device placement. Baseline echocardiographic features were similar between groups.
Intraoperative data
The types of CF-LVADs implanted were the HeartMate II (Thoratec, Pleasanton, CA, USA) (n = 48; 85.7%), HeartWare HVAD (HeartWare, Inc., Framingham, MA, USA) (n = 7; 12.5%) and Ventrassist (Ventracor Ltd, Chatswood, NSW, Australia) (n = 1; 1.8%). Subjects in Group A had a longer cardiopulmonary bypass time (111.3 ± 43.3 vs 92.2 ± 37.9 min). The mean aortic cross-clamp time for the repair group was 21.6 ± 8.6 min, while patients in the other group did not receive aortic cross-clamping. The blood product usage and the dosage of vasoactive drugs, as represented by vasoactive-inotropic score [15] , was similar between groups. In addition, approximately 10-20% in both groups received other concomitant valve procedures (Table 2) .
Adverse events and survival
Overall adverse events are summarized in Table 3 . The mean device support duration was 423.5 ± 438.5 and 493.9 ± 579.6 days (P = 0.63) in Group A and Group B, respectively. There were no differences between groups with respect to adverse events. The estimated on-device survival in Groups A and B were 81.4 ± 6.4 and 84.0 ± 10.6% at 1 year (P = 0.70) and 63.3 ± 10.7 and 84.0 ± 10.6% at 2 years (P = 0.41) (Fig. 1A) . Eleven patients (26.8%) in Group A and 8 patients (53.3%) in Group B were bridged to transplantation. No difference was observed between groups with respect to 2-year survival (71.1 ± 8.1 vs 68.9 ± 13.3, P = 0.91) (Fig. 1B) .
Comparison of post-implant aortic insufficiency progression between groups
A total of 248 post-implant echocardiographic studies were available. Freedom from AI > _moderate was 81.8 ± 9.7 and 45.0 ± 21.1% at 2 years (P = 0.031) in Groups A and B, respectively (Fig. 2) .
Additionally, the proportion of patients who developed AI > _moderate during device support in each group stratified by the baseline aortic root diameter was analysed. The median aortic root diameter was 3.3 cm (range 2.2-4.5 cm). Patients with a baseline aortic root diameter > _3.3 cm were placed into the large aortic root group and those with aortic root diameter <3.3 were placed into the small aortic root group. In the small aortic root group, 5% (1 of 20; mean device duration 479 ± 432 days) in Group A and 0% (0 of 6; 216 ± 187 days) in Group B demonstrated post-implant AI > _moderate. In contrast, for the large aortic root group, 9.5% (2 of 21; 370 ± 448 days) in Group A and 55.6% (5 of 9; 679 ± 685 days) in Group B demonstrated postimplant AI > _moderate (P = 0.002) (Fig. 3A) .
Furthermore, patients were grouped by body surface area (BSA)-indexed aortic root diameters to account for differences in body size among subjects. We chose the 75th percentile (1. 94 cm/m 2 ) of BSA-indexed aortic diameter as our cut-off for a large diameter. In this subgrouping, 83.3% (5 of 6) of Group B patients with larger BSA-indexed root demonstrated moderate or greater AI during device support, while none of Group B subjects with smaller BSA-indexed root (0 of 9) developed significant AI. Vasoactive-inotropic score = dopamine (mg/kg/min) + dobutamine (mg/kg/min) + 100 x epinephrine (mg/kg/min) + 10 x milrinone (mg/kg/ min) + 10 000 x vasopressin (U/kg/min) + 100 x norepinephrine (mg/kg/ min) [15] . Moreover, the only Group B patient with a large BSA-indexed root diameter who did not develop AI had a very short device support period due to receiving heart transplant at the 33th day following device implantation. In contrast, all patients in Group A with large BSA-indexed aortic roots have been free of significant AI (Fig. 3B) . Although measurement of post-implant aortic root diameter was not feasible in 30 of 248 studies (12%), serial post-implant aortic root diameter from available data is shown in Fig. 4 . The post-implant aortic root size appears to increase over time irrespective of repair status, particularly between 1 month and 6 months. There was a non-significant trend towards larger aortic root size in Group B at 12 months.
Clinically significant aortic insufficiency
Among those who demonstrated AI > _moderate during follow-up, 1 (2.4%) in Group A and 1 (6.7%) in Group B developed heart failure symptoms due to AI and required hospitalization. The patient in Group A was confirmed to be free from AI on TTE at 6 months but developed heart failure and was found to have severe AI 205 days following device implantation. He had urgent United Network for Organ Sharing (UNOS) status upgrade and subsequent transplantation. The stitch repair of this patient appeared to be loose with asymmetric leaflet change, specifically elongation of the right coronary cusp (Fig. 5, Patient 1) . A repaired AV without AI from a different patient is shown for comparison (Fig. 5, Patient 2) . The symptomatic patient from Group B was a 74-year-old female. Although free from AI on TTE on postoperative Day 211, she was readmitted on postoperative Day 345 and was found to have AI progression. She received intensified medical management and pump speed optimization and was eventually discharged from hospital without any surgical intervention. This patient remained asymptomatic after discharge, with her most recent TTE on postoperative day 419 revealed moderate AI.
DISCUSSION
Our previous report of concurrent CAVC during a 10-year CF-LVAD experience demonstrated that repaired patients had 57% decrease in the odds of significant post-implant AI progression after adjusting time effect and pre-existing AI degree [9] . Despite these findings, a number of clinical questions remain unanswered and the optimal surgical management of native AI in patients undergoing CF-LVAD implantation remains controversial. Recent guidelines recommend surgical intervention if greater than mild AI is noted preoperatively [10] . This recommendation is based on past studies with small patient populations that have heterogeneous degrees of AI receiving varied AV procedures with relatively short-term device support. This study aims to elucidate whether mild AI should be intervened on in such a population. The primary findings in this study are that adverse events as well as survival were similar in both patient groups, AI progression was much less for patients who underwent repair than for patients who were not repaired, development of significant AI was largely confined to non-repaired patients with large BSAindexed aortic roots and lastly that repair even in patients with large indexed aortic roots protected against the development of significant AI. These findings suggest that patients with mild AI who have large BSA-indexed aortic roots may be the best candidates for CAVC at the time of device implantation, while those with small aortic roots may forgo a repair.
The association between aortic root dilation and AI progression has been examined in previous studies. Fine et al. investigated the relation between proximal thoracic aorta dimension changes and the occurrence of AI in CF-LVAD patients [16] . Proximal thoracic aorta dimensions were observed to increase modestly after implantation of a HeartMate II, predominantly in the first 6 months. Furthermore, this trend was more marked in patients with baseline proximal aortic root >3.5 cm. The cause of this observation has been speculated to be due to increased aortic wall sheer stress and diastolic luminal pressures [2, 16, 17] . The aortic root and aortic valve are subject to high retrograde pressures with large volumes of blood from the outflow cannula. Aortic dilatation with concomitant changes in aortic wall elasticity and chronically high diastolic aortic pressures may promote valve malcoaptation and development of AI [2] . Postoperative AI progression is multifactorial, however, baseline root diameter can be a useful tool for preoperative decision making in performing concomitant AV repair.
Echocardiographically significant AI does not always translate to clinically significant AI. Despite the prevalence of echocardiographically significant AI, the clinical significance of AI in patients with CFLVADs remains unclear. Previous studies report the incidence of clinically significant AI requiring surgical intervention ranges from 2.5 to 3.5% [18] , and similarly, our previous study reported a 3.2% intervention rate [9] . While patients with echocardiographically significant AI require more frequent echocardiographic surveillance and clinical follow-up, no previous studies have reported an increase in mortality due to AI progression. In this study, one patient in Group A was transplanted due to severe AI (Fig. 5) . Survival of the repair group appeared to be lower, particularly after 1 year (Fig. 1A) , although there was no statistical difference with Group B. In our study, the cause of deaths in repaired patients was not related to aortic valve.
Limitations
First, our investigation is a single-institution, retrospective study confounded by evolving patient selection criteria and thresholds for AV repair. Reasons for repair were varied for each patient, and therefore no uniform criteria existed during the study period. Furthermore, our institution did not begin incorporating the Park AV repair technique until 2009; though, there were only 4 patients who received a device before 2009 in the present study cohort. Second, our sample size is small, and thus the study may be underpowered. Furthermore, our 75th percentile cut-off point for aortic root and BSA-indexed aortic root diameter is an arbitrary threshold and this cut-off is not clinically validated by other studies. Moreover, previously outlined contributing factors to AI progression such as female gender, frequency of aortic valve opening and augmented LVAD outputs (with resultant smaller left ventricular volumes) [2, 9] were not correlated with the echocardiographic results in this study due to the small sample size and data unavailability. Third, the serial follow-up echocardiographic studies, which can be often affected by haemodynamics, were performed in various clinical settings such as in the intensive care unit and outpatient clinics. Lastly, much of the controversy rest upon quantifying/ qualifying AI using traditional echocardiography measures. There have been no guidelines to grade AI severity in patients with CFLVADs, and most centres, including our own, use American Society of Echocardiography guidelines, which were never validated in CF-LVAD-supported patients.
CONCLUSION
In summary, AI progression in patients with mild-degree baseline AI undergoing CF-LVADs is quite common. While it is recommended that the AV be intervened on when the AI is more than mild, this study suggests that a subset of patients even with mild AI degree may benefit from an AV repair at the time of device insertion. This study further elucidated that the aortic root diameter may be helpful in identify those patients with mild AI who will benefit from an AV procedure. This repair may help prevent the development of echocardiographic significant AI, however, its clinically significance is still to be determined.
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